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abstract
CONTEXT: Chronic lymphocytic leukemia (CLL) is a clonal
lymphoproliferative disorder, characterized by B lymphocytic prolif-
eration. CLL is the most frequent adult leukemia in Western coun-
tries, accounting for 25 to 30% of all white leukemic patients.
OBJECTIVE: To evaluate clinical and staging characteristics in prog-
nosis of chronic lymphocytic leukemia.
DESIGN: Evaluation of clinical-staging data.
SETTING: Universidade Federal de São Paulo - Escola Paulista de
Medicina / Universidade de Alfenas.
SAMPLE: 73 patients diagnosed from 1977 to 1994.
MAIN MEASUREMENTS: Sex, ethnic origin, age, lymphadenopa-
thy, splenomegaly, hepatomegaly, three or more areas of  lymphoid
enlargement, hemoglobin (g/dl), lymphocytes/mm3, Platelets/mm3
RESULTS: Mean survival of patients was 76 months, median age
was 65 years, ranging from 33 to 87. Forty-four patients (60.3%)
were male and 29 (39.7%) female.
CONCLUSION: The Binet system determined a better prognosis than
Rai.
KEY WORDS: Chronic Lymphocytic Leukemia. Prognosis. Clinical.
Staging.
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INTRODUCTION
Chronic lymphocytic leukemia (CLL) is a clonal
lymphoproliferative disorder, characterized by B lym-
phocytic proliferation.1 CLL is the most frequent adult
leukemia in Western countries, accounting for 25 to
30% of all white leukemic patients.2 The mean age for
the disease is greater than 50 years and the male to
female ratio is 2:1.3 The illness seems to occur in 0.8
new cases per 100,000 persons per year in Brazil.4
Most patients are asymptomatic regarding anemia,
lymph nodes, spleen and/or liver enlargement, as well as
for hemorrhages and infective complications demanding
medical attention.1,5 Rai et al.6 suggested that a persistent
peripheral blood lymphocytic count greater than 15000
per mm3 and lymphocytic marrow cellularity greater than
40% are essential findings for making its diagnosis.
Many studies have been tried, since early in the
20th century, to determine prognostic factors and stag-
ing systems for predicting survival. These studies were
consolidated into the criteria devised by Rai et al.
(1975)6 and Binet et al. (1981).7
Rai’s proposals consisted of 5 established steps:
stage 0 - only lymphocytosis (in blood as well as in
marrow); stage I - lymphocytosis associated with en-
hanced lymph nodes; stage II - lymphocytosis plus liver
and/or spleen enlargement, with or without lymph node
involvement; stage III - lymphocytosis in the presence
of anemia, defined by hemoglobin levels below 11 g/dl;
stage IV - lymphocytosis plus thrombocytopenia, evalu-
ated by a platelet count of less than 100,000 per mm3.6
Binet et al.7 summarized the Rai system and rec-
ommended only three stages, as follows: stage A - pres-
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ence of one or two lymphoid enlargements; B - three or
more areas and C - presence of anemia confirmed by
hemoglobin less than 10 g/dl or thrombocytopenia, with
a platelet count of less than 100,000 per mm3
.
The International Workshop on CLL (1981) rec-
ommended the association of Binet and Rai in order to
analyze clinical and evolution data. The following stages
were suggested: stage A(0), A(I) and A(II) as low risk;
B(I),  B(II) as intermediate and C(III) and C(IV) as high
risk.8 However, in actual practice, this system was not
completely acceptable worldwide, and clinicians have
continued to use either the Binet or Rai methods.9 The
National Cancer Institute (1996) proposed a modified
Rai system as follows: low risk (Rai stage 0); intermedi-
ate risk (Rai stage I plus stage II) and high risk (Rai stage
III plus IV).9 At the moment many other prognostic fac-
tors are being studied, particularly abnormal expres-
sion of oncogenes (Bcl-2, Bcl-X
L
, Bcl-W, Bax, Bak, Mcl-1,
Bag, p-53, and others).10
Our intention here was to evaluate clinical and
staging features in Brazilian CLL patients so as to un-
derstand their prognostic meaning better, by compar-
ing the Binet, Rai, and modified Rai staging systems.
METHODS
One hundred and two CLL patients were admit-
ted into São Paulo Hospital and Alzira Velano Hospi-
tal between 1977 and 1994. The data for 26 of them
were not consistent with what was on their medical
registers, which might have allowed us to determine
either their survival or clinical staging, and 3 other
patients had misinterpreted diagnoses. The 73 remain-
ing patients were included for final evaluation. All of
these fulfilled Binet, Rai and modified Rai staging re-
quirements.
All patients were submitted to conventional
chemotherapy schedules with combinations of oral
chlorambucil and prednisone for early stage disease
or cyclophosphamide, vincristine, prednisone and
adriamycin for advanced disease.
Diagnosis was based on history, physical exami-
nation, presence of more than 5.0 x 103 lymphocytes
per mm3 in peripheral blood, and at least 30% of lym-
phocytic marrow involvement in marrow aspiration
analysis.1 The staging was obtained according to the
Binet,7 Rai6 and modified Rai systems.9 Survival curves
were obtained by limited extrapolation of the Kaplan
& Meier method.11 The curves obtained were compared
using the Wilcoxon and Cox-Mantel tests.12
. 
Multivari-
ate analyses were performed using multiple Cox re-
gressions.13,14 “P” was considered to be significant when
less than 0.05, for all tests. The statistical programs
utilized were: KMSURV - Univariate Survival Data
Analysis, May 89, Ludwig Institute for Cancer Research,
São Paulo Branch - Epidemiology and Biostatistics
Unit; BMDP - Biomedical Data Package - Survival
Analysis with Covariates - Cox Models, May 84, Health
Science Computing Facility, University of California
(UCLA), Los Angeles.14
Table 1. Results of the univariate analysis
Variable Category Number (%) Mean Survival (months) P
Sex Males 44 (60.3%) 61.13 0.09
Females 29 (39.7%) 87.76
Ethnic origin Whites 60 (82.2%) 74.12 0.72
Non-whites 13 (17.8%) 65.15
Age > 65 37 (50.7%) 78.50 0.55
< 65 36 (49.3%) 66.91
Lymphadenopathy Present 40 (54.8%) 53.67 0.27
Absent 33 (45.2%) 82.84
Splenomegaly Present 29 (39.7%) 58.88 0.07
Absent 44 (60.3%) 124.12
Hepatomegaly Present 24 (32.9%) 63.33 0.23
Absent 49 (67.1%) 120.16
Three or more areas of Present 17 (23.3%) 42.47 0.01
lymphoid  enlargement Absent 56 (76.7%) 90.54
Hemoglobin (g/dl) > 10 47 (64.4%) 94.07 0.001
<  10 26 (35.6%) 33.74
Hemoglobin (g/dl) > 11 39 (53.4%) 94.72 0.004
< 11 34 (46.6%) 36.94
Hemoglobin (g/dl) < 10 30 (41.1%) 36.03 0.02
< 12 and >10 20 (27.4%) 67.82
> 12 23 (31.5%) 98.49
Lymphocytes / mm3 > 36,000 37 (50.7%) 54.23 0.03
< 36,000 36 (49.3%) 89.46
Platelets / mm3 > 100,000 58 (79.5%) 88.55 0.03
< 100,000 15 (20.5%) 36.4
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RESULTS
There were 56 (76.7%) live patients at the end of
our observation. Mean survival was 76.1 months, rang-
ing from 1 to 140. Forty-four (60.3%) were male (M)
and 29 (39.7%) female (F), with M/F ratio of 1.52. Mean
age was 63.9 years, ranging from 33 to 87. Mean sur-
vival after the age of 65 years was 78.5 months versus
66.9 before this (P = 0.55). Females had longer sur-
vival than males, but not reaching statistical signifi-
cance (P = 0.09). Table 1 shows the univariate analysis
results. To better compare patients in Binet stages A
and B, all those with anemia and thrombocytopenia
(stage C) were excluded for separated analysis (Table
2). Mean survival according to the Rai, modified Rai
and Binet staging systems is summarized in Table 3.
Univariate and multivariate analysis
Seven variables were compared with prognosis
(survival): 1) hemoglobin levels with cutoffs of 12, 11
and 10 g/dl, with P = 0.02, 0.004 and 0.001, respec-
tively (Figure 1); 2) Binet staging system (P = 0.003;
Figure 2); 3) Rai staging system (P = 0.02); 4) Modified
Rai staging system (P = 0.007); 5) Number of lymphoid
enhancement areas (P = 0.01); 6) Platelet count, with
a cutoff of 100,000 per mm3 (P = 0.03); and 7) Number
of lymphocytes in peripheral blood, greater than 36,000
per mm3 (P = 0.03). However, multivariate analysis only
showed a significant independent effect on survival
for the Binet system.
DISCUSSION
Since the Minot & Isaacs study,15 many other
studies have been carried out with the purpose of bet-
ter establishing the prognosis of patients with CLL.
Rai and Binet reported useful concepts but, so far, no
paper has explained the heterogeneity in the progno-
sis of CLL.16
We began our study with the analysis of patients’
sex. There is agreement in the literature that the inci-
dence is higher in men than in women, with the male/
female ratio being about 2:1.17 Our cases showed a
1.52/1.00 ratio, which confirms the same tendency.
Reports on the importance of patients’ sex on the prog-
nosis are also heterogeneous in their results. Many
authors have reported a better prognosis in women
when compared to men,18-22 while others have not
found a significant difference between the sexes.23-26
Our findings coincide with those of the latter group.
Although we found higher mean survival among fe-
males, the difference was not significant.
Patients’ ages at the time of diagnosis most fre-
quently range between the 6th and 7th decades of life.27
The average age in our cases was 63.9 years, with a
median of 65 years, similar to the literature. The rela-
tionship of age to prognosis is not homogeneous in
the literature. Minot & Isaacs15 and Paolini et al.20 cor-
related low age with a bad prognosis, but Boggs et
al.,23 Hansen18 and Lee et al.21 reported the opposite.
Although we found a higher mean survival in patients
aged over 65 years, age differences were not statisti-
cally significant in our study (P = 0.55).
The incidence of CLL in Africa seems to be lower
when we compare it with the incidence in white men.
According to Linet & Cartwright,27 this fact is due not
to low incidence among black people, but to the lack
of diagnosis. We consider that it is not advisable to
analyze prognosis in relation to race in Brazil, in view
of the great interracial mixing in this country. We found
a higher incidence in white patients (82.2%). However,
this does not permit us to conclude that there is a
genuinely low incidence in black people. The skin color
was not significant in survival (P = 0.72).
No difference was found in our study regarding
the mean of patients’ survival when we analyzed the
presence of adenomegaly, splenomegaly and
hepatomegaly (Table 1). Nevertheless, when we ana-
lyzed the presence of more than 3 areas of infiltration,
there was a significant relation with survival (P = 0.01).
As there was a significant difference in the sur-
vival of patients in Binet’s stages A and B, we performed
the analyses of the same clinical variables, excluding
the patients with anemia and/or thrombocytopenia, to
avoid the effect of these latter variables on the progno-
sis. Thus, in patients without anemia and/or thromb-
ocytopenia, we observed that the presence of both
adenomegaly (P = 0.04) and splenomegaly (P = 0.02)
caused a lower survival. Hepatomegaly showed lesser
importance in the determination of survival (P = 0.06)
and the number of affected areas was the most statisti-
cally significant parameter (P = 0.01). These findings
permit us to conclude that prognosis really changes with
the extent of the disease (Table 2).
Table 2. Mean survival (months) of patients
considering clinical variables except anemia and
thrombocytopenia
Variable Present Absent P
Lymphadenopathy 56.49 115.25 0.04
Splenomegaly 73.92 140.00 0.02
Hepatomegaly 79.26 140.00 0.06
Three or more areas of 52.05 115.25 0.01
lymphoid enlargement
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Among the clinical variables, hemoglobin exhib-
ited the most significant relationship with survival. Ac-
cording to various authors,6,7,15,18,23,24,28 hemoglobin is one
of the most important variables in the survival of pa-
tients with CLL, and our results agree with those in the
literature. We first analyzed hemoglobin at two cutoff
levels (10 g/dl and 11 g/dl). As we found a significant
relationship with survival at both levels (P = 0.001 and
0.004, respectively), we subdivided the hemoglobin lev-
els into three groups (Hb = 10 g/dl, 10 g/dl < Hb < 12 g/
dl and Hb = 12 g/dl). Even with the subdivision into
three groups, the hemoglobin levels kept a significant
relationship with survival (P = 0.006), showing a mean
survival time of 36.20 months, 68.45 months, and 98.49
months, respectively. We have thus demonstrated that,
as the levels of hemoglobin decrease, the patients’
mean survival time also decreases. The hemoglobin
threshold for the determination of anemia was arbi-
trarily chosen as 10 g/dl in Binet’s staging and 11 g/dl in
Rai’s staging. Hence, we think that patients with C(III)
staging should not be considered in relation only to
the presence of anemia, but should also be evaluated
for hemoglobin level as a prognosis determinant, as
progressively lower hemoglobin values lead to progres-
sively worse prognoses (Table 1, Figure 1).
A platelet count lower than 100,000 per mm3 (P
= 0.02) represented a significant prognosis, as well as
a lymphocyte count of greater than 36,000 per mm3 (P
= 0.03). With regard to platelet count, our results agree
with those of Rai et al.,6 but disagree with others.21,31-33
For the latter, anemia should be a more relevant fac-
tor than thrombocytopenia. The prognostic signifi-
cance of the lymphocyte count is controver-
sial.15,18,19.24,25,29-31 In our observations, with cutoffs at
50,000/mm3, 100,000/mm3, and 150,000/mm3, we found
no significant relationship with survival, probably be-
cause patients with more than 36,000 per mm3 may
present a worse prognosis, as was also observed by
Baccarani et al.30
We found that the three most important clini-
cal variables for prognosis of CLL patients are hemo-
globin with a cutoff at 10 g/dl (P = 0.001); number of
lymphoid infiltration areas (P = 0.01), showing our
agreement with the parameters for determination of
groups A, B and C of the Binet staging system;7 and
peripheral lymphocytosis (P = 0.03).
After evaluating our patients in accordance with
Rai’s staging, our findings agree with those in the lit-
erature. There was a significant difference in survival
in our groups, but it did not decrease from stage 0 to
stage IV. Survival was shorter in stage I than in stage
II, but it may have occurred due to the sample size (6
patients) and a briefer follow-up. Moreover, all of them
were alive at the end of this study. Survival in stage IV
was not shorter than in stage III, which suggested that
the platelet count may not have significant importance
in the prognosis of CLL.
Table 3 - Mean Survival (months) according to the Rai,
Binet and modified Rai staging systems
Stage Number (%) Survival P
Rai
O*    11 (15.0) 140.00 0.02
I*     6 (08.2) 27.00
II    26 (35.6) 79.82
III   14 (19.1) 13.17
IV   16 (21.9) 36.46
Binet
A 29 (40.7%) 115.25 0.003
B 14 (19.2%) 52.05
C 30 (41.1%) 31.01
Modified Rai
Low risk* 11 (15.0%) 140.00 0.007
Intermediate risk 32 (43.9%) 83.34
High risk 30 (41.1%) 32.01
*All patients were alive at the time of cutoff.
Figure 1 - Survival of CLL patients according to hemoglobin (Hb) level.
P
Figure 2 - Survival of CLL patients according to Binet staging system.7
P
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Although classic, the Rai system subdivides the
disease into 5 stages, making the treatment approach
more difficult due to the great number of subgroups.
Moreover, Rai considers that liver and spleen infil-
tration occurs later than lymph node enlargement.
Some authors18,23,28 have not infrequently observed
cases of marked splenomegaly in the absence of
adenomegaly. The modified Rai system is similar to
the Binet system and was significant in the univariate
analysis (P = 0.007), but despite the small number of
groups the multivariate analysis showed that the Bi-
net method expresses a better prognosis of CLL. We
have also demonstrated that both the hemoglobin
level and the number of lymphoid areas involved, as
seen by Binet et al.,7 correlate with survival in the
univariate analysis. However, only the Binet system
remained significant in the multivariate analysis, be-
ing a simpler and more accurate method for evaluat-
ing the prognosis of CLL.
CONCLUSIONS
The significant variables in the univariate analy-
sis were: number of areas with enlarged lymphoid, he-
moglobin, platelets, peripheral lymphocytosis and Rai,
modified Rai and Binet systems. Multivariate analysis
showed Binet staging is better than Rai and modified
Rai for evaluating prognosis.
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resumo
CONTEXTO: Diversas variáveis clínicas se relacionam ao prognóstico
na leucemia linfocítica crônica; no entanto, o estadiamento de Binet
determina melhor o prognóstico do que o estadiamento de Rai e Rai
modificado.
OBJETIVO: Avaliar características clínicas e laboratoriais no
prognóstico da leucemia linfocítica crônica.
TIPO DE ESTUDO: Estudos de correlação.
LOCAL: Universidade Federal de São Paulo - Escola Paulista de
Medicina / Universidade de Alfenas.
PARTICIPANTES: 73 patients diagnosticados entre 1977 e 1994.
VARIÁVEIS ESTUDADAS: Sexo, origem étnica, idade,
linfadenomegalia, esplenomegalia, hepatomegalia,  três ou mais
áreas com aumento linfóide, hemoglobina, linfocitos, plaquetas.
RESULTADOS: A sobrevida média dos pacientes foi 76 meses, idade
média de 65 anos, variando de 33 a 87 anos. Quarenta e quatro
pacientes (60,3%) eram do sexo masculino e 29 (39,7%) do sexo
feminino. A análise univariada mostrou que o nível de hemoglobina
(P = 0,001), número de plaquetas (P = 0,03), linfocitose periférica
(P = 0,03), número de áreas linfóides acometidas (P = 0,01), assim
como os estadiamentos de Rai (P = 0,02), Rai modificado (0,007) e
Binet (P = 0,003) relacionaram-se significantemente com a sobrevida.
A análise multivariada, pela regressão de Cox, demonstrou que o
sistema de Binet determina melhor o prognóstico do que os
estadiamentos de Rai e Rai modificado.
CONCLUSÃO: O estadiamento de Binet é melhor que o estadiamento
de Rai e Rai modificado na determinação do prognóstico.
PALAVRAS-CHAVE: Leucemia linfocítica crônica. Prognóstico.
Clínica. Estadiamento.
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